|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers
The purpose of this study is to evaluate if the investigational medicinal product CHRONSEAL intended for future treatment of chronic venous leg ulcers is safe and tolerated and if it has an ulcer size reduction effect when administered to individuals suffering from venous leg ulcers.
100 项与 Kringle Pharma Europe AB 相关的临床结果
0 项与 Kringle Pharma Europe AB 相关的专利(医药)
100 项与 Kringle Pharma Europe AB 相关的药物交易
100 项与 Kringle Pharma Europe AB 相关的转化医学